<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>T cells from patients who had received chemotherapy for B-lineage <z:hpo ids='HP_0011009'>acute</z:hpo> lymphocytic <z:hpo ids='HP_0001909'>leukemia</z:hpo> were studied to determine whether genetic instability, a principal characteristic of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> cells, can also occur in nonmalignant cells </plain></SENT>
<SENT sid="1" pm="."><plain>Consistent with expectations for a genetic instability phenotype, multiple mutations were detected in the <z:chebi fb="0" ids="17368">hypoxanthine</z:chebi>-<z:chebi fb="1" ids="16235">guanine</z:chebi> phosphoribosyltransferase (HPRT) reporter gene in independently isolated mutant T cells expressing identical rearranged T cell receptor beta (TCRbeta) gene hypervariable regions </plain></SENT>
<SENT sid="2" pm="."><plain>These results indicate that <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> treatment can lead to genetic instability in nonmalignant cells in some individuals </plain></SENT>
<SENT sid="3" pm="."><plain>They also suggest a mechanistic paradigm for the induction of <z:e sem="disease" ids="C0085183" disease_type="Neoplastic Process" abbrv="">second malignancies</z:e> and drug resistance </plain></SENT>
</text></document>